Adriaan J. van der Meer
A5045283839- Liver Disease Diagnosis and Treatment
- Hepatitis C virus research
- Liver Diseases and Immunity
- Hepatitis B Virus Studies
- Pediatric Hepatobiliary Diseases and Treatments
- Liver Disease and Transplantation
- Gallbladder and Bile Duct Disorders
- MicroRNA in disease regulation
- Transplantation: Methods and Outcomes
- Hepatocellular Carcinoma Treatment and Prognosis
- Systemic Lupus Erythematosus Research
- COVID-19 and healthcare impacts
- Acute Lymphoblastic Leukemia research
- Organ Transplantation Techniques and Outcomes
- RNA Research and Splicing
- Celiac Disease Research and Management
- Hepatitis Viruses Studies and Epidemiology
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Drug Transport and Resistance Mechanisms
- Extracellular vesicles in disease
- Viral-associated cancers and disorders
- Healthcare cost, quality, practices
- Genetic and Kidney Cyst Diseases
- Sexual Differentiation and Disorders
- Automotive and Human Injury Biomechanics
Erasmus MC
2016-2025
Erasmus University Rotterdam
2013-2025
Erasmus MC Cancer Institute
2024-2025
Erasmus MC Transplant Institute
2025
ERN GUARD-Heart
2025
ERN RARE-LIVER
2025
Universität Hamburg
2025
University Medical Center Hamburg-Eppendorf
2025
Medical University of Warsaw
2025
Radboud University Nijmegen
2022
The stability and propagation of hepatitis C virus (HCV) is dependent on a functional interaction between the HCV genome liver-expressed microRNA-122 (miR-122). Miravirsen locked nucleic acid-modified DNA phosphorothioate antisense oligonucleotide that sequesters mature miR-122 in highly stable heteroduplex, thereby inhibiting its function.In this phase 2a study at seven international sites, we evaluated safety efficacy miravirsen 36 patients with chronic genotype 1 infection. were randomly...
<h3>Context</h3>Chronic hepatitis C virus (HCV) infection outcomes include liver failure, hepatocellular carcinoma (HCC), and liver-related death.<h3>Objective</h3>To assess the association between sustained virological response (SVR) all-cause mortality in patients with chronic HCV advanced hepatic fibrosis.<h3>Design, Setting, Patients</h3>An international, multicenter, long-term follow-up study from 5 large tertiary care hospitals Europe Canada of 530 who started an interferon-based...
MicroRNA-122 (miR-122) is an important host factor for hepatitis C virus replication. Administration of miravirsen, anti-miR-122 oligonucleotide, resulted in a dose dependent and prolonged decrease HCV RNA levels chronic patients.To assess the plasma level various miRNAs patients dosed with miravirsen.We included 16 36 who received five injections either 3 mg/kg (n = 4), 5 7 4) miravirsen or placebo over 4-week period double-blind, randomised phase 2a study. Plasma 179 were determined by...
Morbidity and mortality attributable to chronic hepatitis C virus (HCV) infection are increasing in many countries as the infected population ages. Models were developed for 15 quantify characterize viremic population, well estimate number of new infections HCV related deaths from 2013 2030. Expert consensus was used determine current treatment levels outcomes each country. In most countries, prevalence has already peaked. every country studied, begins decline before 2030, when held...
HCV-infected patients with cirrhosis achieve high sustained virological response (SVR) rates direct-acting antivirals (DAAs) even after hepatic decompensation. We aimed to assess the clinical outcome following DAAs among compensated and decompensated in relation SVR changes model for end-stage liver disease (MELD) score.Consecutive DAA-treated chronic from 4 hepatology clinics were included. The primary endpoint survival analyses was progression, defined as failure, hepatocellular carcinoma,...
INTRODUCTION: In primary biliary cholangitis (PBC), bilirubin and alkaline phosphatase (ALP) are widely established as independent predictors of prognosis. Current treatment goals do not aim for normalization surrogate markers because their association with survival has been defined. METHODS: The patient cohort from the GLOBAL PBC Study Group was used, comprising long-term follow-up data European North American centers. Ursodeoxycholic acid-treated untreated patients levels ≤1 × upper limit...
Summary Chronic hepatitis C virus ( HCV ) infection is a leading cause of liver related morbidity and mortality. In many countries, there lack comprehensive epidemiological data that are crucial in implementing disease control measures as new treatment options become available. Published literature, unpublished expert consensus were used to determine key parameters, including prevalence, viremia, genotype the number patients diagnosed treated. this study 15 viremic prevalence ranged from...
Background & AimsThe Primary Biliary Cholangitis (PBC) Obeticholic Acid (OCA) International Study of Efficacy (POISE) randomized, double-blind, placebo-controlled trial demonstrated that OCA reduced biomarkers associated with adverse clinical outcomes (ie, alkaline phosphatase, bilirubin, aspartate aminotransferase, and alanine aminotransferase) in patients PBC. The objective this study was to evaluate time first occurrence liver transplantation or death the POISE open-label extension vs...
Summary As chronic hepatitis C patients with progressive disease can present themselves normal ALT levels, more sensitive biomarkers are needed. Micro RNA s newly discovered small noncoding that stable and detectable in the circulation. We aimed to investigate association between hepatocyte‐derived micro serum liver injury . The mi R ‐122 ‐192 were analysed sera of 102 HCV ‐infected 24 healthy controls. Serum levels correlated strongly ( = 0.67 0.65, respectively, P < 0.001 for both)....
Summary The hepatitis C virus ( HCV ) epidemic was forecasted through 2030 for 15 countries, and the relative impact of two scenarios considered: (i) increased treatment efficacy while holding treated population constant (ii) annual population. Increasing levels diagnosis treatment, in combination with improved efficacy, were critical achieving substantial reductions disease burden. In most had to increase several fold achieve largest ‐related morbidity mortality. This suggests that capacity...
Patients with chronic hepatitis B (CHB) are at increased risk of hepatocellular carcinoma and (liver-related) mortality. In addition to B-related factors, metabolic comorbidities may contribute the progression fibrosis. Therefore, we studied association between adverse clinical outcomes in patients CHB.We conducted a retrospective cohort study CHB attending Erasmus MC University Medical Center (Rotterdam, The Netherlands) who underwent liver biopsy Toronto General Hospital (Toronto, Canada)....
Patients with chronic hepatitis C virus (HCV) infection may develop cirrhosis portal hypertension, reflected by decreased platelet count and splenomegaly. This retrospective cohort study aimed to assess changes in counts after antiviral therapy among HCV-infected patients advanced fibrosis.Platelet spleen sizes were recorded an international of Ishak 4-6 fibrosis who started between 1990 2003. Last measured compared their pre-treatment values (within 6 months prior the start therapy). All...
Background: Impaired health-related quality of life (HRQoL) contributes to the overall disease burden in autoimmune hepatitis (AIH). This study aimed evaluate HRQoL people with AIH and identify potentially modifiable factors associated impaired using validated patient-reported outcome measures. Methods: Adult patients diagnosed at 12 European centers were enrolled this prospective, cross-sectional from July 2020-June 2023. was assessed Physical Component Score (PCS) Mental (MCS) 12-item...
<h3>Objective</h3> Reliable tools to predict long-term outcome among patients with well compensated advanced liver disease due chronic HCV infection are lacking. <h3>Design</h3> Risk scores for mortality and cirrhosis-related complications were constructed Cox regression analysis in a derivation cohort evaluated validation cohort, both including fibrosis. <h3>Results</h3> In the 100/405 died during median 8.1 (IQR 5.7–11.1) years of follow-up. Multivariate analyses showed age (HR=1.06, 95%...